Devita, Hellman, and Rosenberg's Cancer

LWBK1006-20 LWW-Govindan-Review December 12, 2011 19:4

246 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 20.2.10.Mutation of which tumor suppressor gene is most frequently associated

with familial pancreatic cancer?

A. BRCA2

B. PALB2

C. K-RAS

D. TP53

Question 20.2.11.Which of the following statements regarding risk factors for pancreatic

cancer is CORRECT?

A. ABO blood group is associated with increased risk for pancreatic

cancer.

B. Testing for K-RAS mutations in the pancreatic juice of patients is an

effective screening test for pancreatic cancer in high risk patients.

C. Patients with hereditary nonpolyposis colorectal cancer syndrome do

not have an increased risk for pancreatic cancer.

D. Hereditary pancreatitis is not a significant risk factor for pancreatic

cancer.

Question 20.2.12.A 65-year-old male was diagnosed with metastatic pancreatic cancer and

received treatment with single-agent gemcitabine. However, he now has

disease progression and is interested in pursuing systemic therapy. Which

of the following could be considered as a second-line treatment choice?

A. FOLFOX6

B. Erlotinib

C. Paclitaxel

D. Irinotecan and raltitrexed

Question 20.2.13.Which of the following is true about pancreatic cancer?

A. Most pancreatic cancers have mutations in KRAS, TP53, SMAD4,

p16/CDKN2A.

B. Telomere shortening is the earliest and most prevalent genetic change

identified in the precursor lesions.

C. Underexpression of TGF-is observed in few pancreatic cancers.

D. p16-mediated CDK inhibition is a protective mechanism against pan-

creatic cancer.

E. All of above.